Recalls & Warnings November 25, 2017 Seller of "BounceBack" Joint Supplement and Others Products Warned for Drug Claims On November 14, 2017, the FDA sent a warning letter to Mannatech Incorporated following a facility inspection that found the products BounceBack, MannaBears, ImmunoSTART, TruSHAPE, and Catalyst to be in violation of the Current Good Manufacturing
Kaneda, T
*Before starting any new nutrition regimen or supplementation, consult with your healthcare provider and/or registered dietitian and nutritionist
Recent clinical trials of agents like trastuzumab deruxtecan, datopotamab deruxtecan, and sacituzumab govitecan have demonstrated meaningful objective response rates and manageable toxicity, offering hope for patients with advanced NSCLC and SCLC
Kolek MJ, Graves AJ, Xu M, et al
Tumour Biol 2014;35(1):247-256